Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14384487 | 1.00 | KMT2A (0.45) | KMT2AMEN1HPGDNPSR1KDM4E | |
| SCHEMBL23352294 | 0.98 | KMT2A (0.43) | KMT2AMEN1HPGDNPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL16038209 | 0.87 | KMT2A (0.49) | KMT2AMEN1HPGDNPSR1KDM4E | |
| Hydrochloric Acid SCHEMBL16037851 | 0.85 | KMT2A (0.46) | KMT2AMEN1HPGDNPSR1KDM4E | |
| SCHEMBL16448942 | 0.85 | HCAR2 (0.53) | KMT2AMEN1HPGDNPSR1KDM4E | |
| SCHEMBL16448940 | 0.85 | ACHE (0.47) | KMT2AMEN1HPGDNPSR1KDM4E | |
| SCHEMBL16090954 | 0.85 | KMT2A (0.44) | KMT2AMEN1HPGDNPSR1KDM4E | |
| SCHEMBL16435308 | 0.85 | KMT2A (0.44) | KMT2AMEN1HPGDNPSR1KDM4E | |
| SCHEMBL15171911 | 0.85 | KMT2A (0.44) | KMT2AMEN1HPGDNPSR1KDM4E | |
| SCHEMBL22782066 | 0.84 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| US-20090143368-A1 | Use of Cinnamoyl Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | COL2A1, MMP7, COL14A1 | KMT2A 4362/4885MEN1 2870/4885HPGD 1386/4885 |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | NPC1, CES2, CYP51A1 | KMT2A 3443/4885MEN1 876/4885HPGD 1703/4885 |
| US-20090143368-A1 | Use of Cinnamoyl Compound | COL2A1, COL1A1, SMAD2 | KMT2A 2275/4885MEN1 3367/4885HPGD 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.